PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide, and immune checkpoint blockade therapy provides an opportunity for improving the outcome of CRC patients. Recent studies suggest that programmed death ligand-1 (PD-L1) is only expressed in 12% of CRCs. Here, we demonstrat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncoimmunology
Päätekijät: Wang, Huanbin, Yao, Han, Li, Chushu, Liang, Lunxi, Zhang, Yao, Shi, Hubing, Zhou, Chongzhi, Chen, Yingxuan, Fang, Jing-Yuan, Xu, Jie
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2017
Aiheet:
Brief Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543903/
https://ncbi.nlm.nih.gov/pubmed/28811964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1327494
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia